296 related articles for article (PubMed ID: 16868547)
1. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
2. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
De Pas TM; Toffalorio F; Giovannetti E; Radice D; Russo F; Angeli I; Calamai G; Spitaleri G; Catania C; Noberasco C; Milani A; Pelosi G; Danesi R; De Braud F
J Thorac Oncol; 2011 Apr; 6(4):768-73. PubMed ID: 21336182
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
4. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
Adjei AA
Lung Cancer; 2001 Dec; 34 Suppl 4():S103-5. PubMed ID: 11742712
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
Adjei AA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):30-4. PubMed ID: 12571808
[TBL] [Abstract][Full Text] [Related]
8. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
Nannizzi S; Veal GJ; Giovannetti E; Mey V; Ricciardi S; Ottley CJ; Del Tacca M; Danesi R
Cancer Chemother Pharmacol; 2010 Aug; 66(3):547-58. PubMed ID: 20020129
[TBL] [Abstract][Full Text] [Related]
9. The pemetrexed/gemcitabine combination in pancreatic cancer.
Kindler HL
Cancer; 2002 Aug; 95(4 Suppl):928-32. PubMed ID: 12209673
[TBL] [Abstract][Full Text] [Related]
10. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed in pancreatic cancer.
Kindler HL
Semin Oncol; 2002 Dec; 29(6 Suppl 18):49-53. PubMed ID: 12571811
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
13. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
14. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
Ngeow J; Toh CK
Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
16. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
18. [Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro].
Zhu ZX; Zhang WM; Jia G; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):149-52. PubMed ID: 20118008
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed in pancreatic cancer.
Seitz JF; Dahan L; Ries P
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):43-7. PubMed ID: 15655936
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
